Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study of cefadroxil effectiveness in adult patients with Staphylococcus aureus bloodstream infection

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on Staphylococcus aureus bacteremia, which is a serious blood infection caused by bacteria called Staphylococcus aureus. The study will investigate how the antibiotic cefadroxil works in treating this type of infection. This medication belongs to a group of antibiotics that are taken by mouth in the form of hard capsules.

The purpose of this research is to understand how the body processes and responds to cefadroxil in patients who have a bloodstream infection. The study will examine how the medication moves through the body and how effective it is at fighting the infection. Participants will receive cefadroxil capsules for up to 6 months, with a maximum daily dose of 4 grams.

During the study, researchers will monitor how well the treatment works and watch for any side effects that may occur. The medication will only be given to patients whose infection has already shown improvement with initial treatment and who can take medications by mouth. This research will help determine the most appropriate dosing of cefadroxil for treating this type of infection.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    After being diagnosed with Staphylococcus aureus bloodstream infection, your eligibility for the study will be evaluated

    Your current treatment with intravenous antibiotics must show improvement

    Blood tests must confirm that the infection is no longer present in your blood

  2. Step 2

    Medication transition

    You will begin taking Cefadroxil Sandoz in the form of hard capsules

    The capsules are taken by mouth

    This transition must occur within 7 days of your first negative blood culture

  3. Step 3

    Treatment monitoring

    Your blood levels of the antibiotic will be measured to ensure proper dosing

    Medical staff will monitor your response to the treatment

    Any side effects or adverse reactions will be recorded

  4. Step 4

    Follow-up period

    Your progress will be monitored for 90 days

    The medical team will check for any signs of infection return

    Any hospital readmissions or changes in your condition will be documented

  5. Step 5

    Study completion

    The study will evaluate if the treatment was successful

    Success is measured by: no return of infection, no need to change antibiotics, and no complications related to the infection

    Your participation will end after the 90-day monitoring period

Who can join the trial?

7 criteria

  • Must be 18 years or older
  • Must be able to understand and provide informed consent to participate in the study
  • Must have a confirmed Staphylococcus aureus bloodstream infection (diagnosed through blood tests and showing signs of infection)
  • Must show improvement in condition after receiving initial antibiotics through an IV
  • Must have at least one negative blood test showing the infection is clearing
  • Must be able to swallow and properly absorb oral medications (no problems with digestion or absorption of medicines)
  • Must be within 7 days of first negative blood culture result

Who cannot join the trial?

14 criteria

  • Age below 18 years or above 65 years
  • Known allergy or hypersensitivity to cefadroxil or other similar antibiotics
  • Pregnant or breastfeeding women
  • Severe kidney problems (as this may affect how the body processes the antibiotic)
  • Current participation in other clinical trials
  • History of serious adverse reactions to antibiotics
  • Presence of other serious infections besides Staphylococcus aureus in the blood
  • Severe liver disease
  • Compromised immune system
  • Taking medications that could interact with cefadroxil
  • Unable to provide informed consent
  • History of seizures or neurological disorders
  • Severe heart conditions
  • Active cancer treatment
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Cefadroxil is an antibiotic medication that belongs to the cephalosporin family of antibiotics. It is used to treat bacterial infections, specifically in this case to treat bloodstream infections caused by Staphylococcus aureus bacteria. The medication works by stopping the growth of bacteria by preventing them from building their cell walls. It is typically taken orally and helps the body fight off the infection by eliminating the harmful bacteria from the bloodstream.

What is already known about the treatment

Cefadroxil - A first-generation cephalosporin antibiotic that is administered orally and used to treat bacterial infections, particularly those caused by Staphylococcus aureus in the bloodstream. The medication works by interfering with bacterial cell wall synthesis, preventing the bacteria from growing and multiplying, ultimately leading to their death. As a beta-lactam antibiotic in the cephalosporin family, it demonstrates good absorption in the digestive system and provides effective coverage against many gram-positive bacteria, making it particularly useful for treating staphylococcal infections. The drug has been well-documented in medical literature and continues to be an important treatment option in modern antibiotic therapy.

Investigated diseases

Staphylococcus aureus bacteremia - A bloodstream infection caused by the bacteria Staphylococcus aureus, which enters and spreads through the blood. The condition occurs when these bacteria, commonly found on the skin, enter the bloodstream through wounds, medical devices, or other routes. The infection can cause fever, chills, and general weakness. The bacteria can multiply rapidly in the bloodstream, leading to the body's inflammatory response. Over time, if present in the bloodstream, the bacteria may spread to different parts of the body.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2025-522547-17-00Estimated enrolment25 patientsSponsorUZ Brussel

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.